[go: up one dir, main page]

AR072226A1 - Derivados triciclicos sustituidos, proceso e intermediario para su sintesis y su uso en medicamentos para el tratamiento de enfermedades mediadas por la actividad de gsk3beta. - Google Patents

Derivados triciclicos sustituidos, proceso e intermediario para su sintesis y su uso en medicamentos para el tratamiento de enfermedades mediadas por la actividad de gsk3beta.

Info

Publication number
AR072226A1
AR072226A1 ARP090102314A ARP090102314A AR072226A1 AR 072226 A1 AR072226 A1 AR 072226A1 AR P090102314 A ARP090102314 A AR P090102314A AR P090102314 A ARP090102314 A AR P090102314A AR 072226 A1 AR072226 A1 AR 072226A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
perhalogenated
halogenated
alkoxy
Prior art date
Application number
ARP090102314A
Other languages
English (en)
Inventor
Alistair Lochead
Mourad Saady
Philippe Yaiche
Garcia Antonio Almario
Original Assignee
Mitsubishi Tanabe Pharma Corp
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Sanofi Aventis filed Critical Mitsubishi Tanabe Pharma Corp
Publication of AR072226A1 publication Critical patent/AR072226A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)

Abstract

Uso en tratamiento terapeutico en el tratamiento de enfermedades neurodegenerativas, c ncer y diabetes. Reivindicacion 1: Un derivado tric¡clico representado por la formula (1) o una sal del mismo, donde: Z representa un enlace, un grupo carbonilo o un grupo metileno opcionalmente sustituido con uno o dos grupos elegidos entre un grupo alquilo C1-6, un grupo hidroxilo o un grupo alcoxi C1-6; R1 representa un anillo de 4-piridina o un anillo de 4-pirimidina; R2 representa un  tomo de hidrogeno; R3 representa: un  tomo de hidrogeno; un grupo fenilo o naftilo, estando estos grupos opcionalmente sustituidos con 1 a 4 sustituyentes seleccionados entre un grupo alquilo C1-6, un  tomo de halogeno, un grupo alquilo C1-2 perhalogenado, un grupo alquilo C1-3 halogenado, un grupo hidroxilo o un grupo alcoxi C1-6 un grupo alcoxi C1-2 perhalogenado, un grupo alquil C1-6-sulfonilo, un nitro, un ciano, un amino, un grupo monoalquil C1-6-amino o un grupo dialquil C2-12-amino, un grupo acetoxi, un grupo aminosulfonilo o un grupo heteroc¡clico, estando este grupo heteroc¡clico opcionalmente sustituido con un grupo alquilo C1-6, un  tomo de halogeno, un grupo alquilo C1-2 perhalogenado, un grupo alquilo C1-3 halogenado, un grupo hidroxilo o un grupo alcoxi C1-6; un grupo heteroarom tico de 5, 6 o 5-6 miembros, estando este grupo opcionalmente sustituido con 1 a 4 sustituyentes seleccionados entre un grupo C1-6 alquilo, un  tomo de halogeno, un grupo alquilo C1-2 perhalogenado, un grupo alquilo C1-6 halogenado, un grupo hidroxilo, un grupo alcoxi C1-6, un grupo alcoxi C1-6 halogenado, un nitro, un ciano, un amino, un grupo monoalquilamino C1-6, un grupo dialquilamino C2-12, un grupo S-(alquilo C1-6), un C(O)O(alquilo C1-6) o un grupo C(O)O(fenilo); n representa un numero entero de 0 a 3; m representa de 0 a 1; en forma de una base libre o de una sal de adicion con un  cido; con la condicion de que no se incluya el compuesto de formula (1) en la que n y m representan 0, Z representa un enlace, R2 y R3 representan un  tomo de hidrogeno y R1 representa un anillo de 4-piridina.
ARP090102314A 2008-06-26 2009-06-24 Derivados triciclicos sustituidos, proceso e intermediario para su sintesis y su uso en medicamentos para el tratamiento de enfermedades mediadas por la actividad de gsk3beta. AR072226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290616A EP2138498A1 (en) 2008-06-26 2008-06-26 Substituted tricyclic derivatives against neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AR072226A1 true AR072226A1 (es) 2010-08-11

Family

ID=39865107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102314A AR072226A1 (es) 2008-06-26 2009-06-24 Derivados triciclicos sustituidos, proceso e intermediario para su sintesis y su uso en medicamentos para el tratamiento de enfermedades mediadas por la actividad de gsk3beta.

Country Status (16)

Country Link
US (1) US8273758B2 (es)
EP (2) EP2138498A1 (es)
JP (1) JP5501354B2 (es)
KR (1) KR20110036081A (es)
CN (1) CN102076693A (es)
AR (1) AR072226A1 (es)
AU (1) AU2009263849A1 (es)
BR (1) BRPI0914538A2 (es)
CA (1) CA2728728A1 (es)
EA (1) EA201170097A1 (es)
IL (1) IL210177A0 (es)
MX (1) MX2010013938A (es)
NZ (1) NZ590044A (es)
TW (1) TW201004959A (es)
WO (1) WO2009156863A2 (es)
ZA (1) ZA201009268B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB2548839B (en) * 2016-03-29 2021-02-24 Great Matter Pharma Ab New uses and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5170780A (ja) 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinabenzoguanidoruino seiho
EG13192A (en) 1976-02-10 1982-12-31 Rhone Poulenc Ind Nouveaux derives du dithiole-1,2 leur preparation et les compositions qui les contiennent
HU178496B (en) 1977-12-29 1982-05-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 6,7,8,9-tetrahydro-4h-pyrido/1,2-a/pyrimidine derivatives with antiallergic activity
US4406897A (en) 1981-07-06 1983-09-27 William H. Rorer, Inc. 6-Aryl-4-hydrazinyl-s-triazin-2-ones
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
CA2234641A1 (en) 1995-11-01 1997-05-09 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
WO2001070728A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
EP1136484A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Arylalkylamino)pyrimidone derivatives
US20050009843A1 (en) 2001-04-26 2005-01-13 Kiyoshi Nakayama Medicine for inhibiting drug elimination pump
DE60206946T2 (de) * 2001-09-21 2006-07-27 Sanofi-Aventis Substituierte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)onderivate gegen neurodegenerative erkrankungen
CA2495661C (en) 2002-08-16 2011-06-14 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta
EP1454909B1 (en) * 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
EP1460076A1 (en) 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1790649A1 (en) 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2138495A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138492A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives

Also Published As

Publication number Publication date
US8273758B2 (en) 2012-09-25
WO2009156863A3 (en) 2010-03-18
EP2307416A2 (en) 2011-04-13
CA2728728A1 (en) 2009-12-30
IL210177A0 (en) 2011-03-31
EA201170097A1 (ru) 2011-08-30
AU2009263849A1 (en) 2009-12-30
CN102076693A (zh) 2011-05-25
WO2009156863A2 (en) 2009-12-30
EP2138498A1 (en) 2009-12-30
KR20110036081A (ko) 2011-04-06
JP5501354B2 (ja) 2014-05-21
EP2307416B1 (en) 2013-08-21
TW201004959A (en) 2010-02-01
US20110224220A1 (en) 2011-09-15
BRPI0914538A2 (pt) 2015-12-15
ZA201009268B (en) 2012-03-28
NZ590044A (en) 2011-11-25
MX2010013938A (es) 2011-09-27
JP2011525907A (ja) 2011-09-29

Similar Documents

Publication Publication Date Title
AR072227A1 (es) Derivados de triazinona sustituidos
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
AR070274A1 (es) Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR064454A1 (es) Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR072226A1 (es) Derivados triciclicos sustituidos, proceso e intermediario para su sintesis y su uso en medicamentos para el tratamiento de enfermedades mediadas por la actividad de gsk3beta.
AR072224A1 (es) Derivados de pirimidona sustituidos
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
AR061739A1 (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
AR060401A1 (es) Derivados de cromen-2-ona
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
AR053082A1 (es) DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS.
AR066605A1 (es) Derivados de heteroarilamida pirimidona
AR066604A1 (es) Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente.
AR070273A1 (es) Derivados de heteroarilamida diazepinopirimidinona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR063577A1 (es) Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos
AR070264A1 (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos

Legal Events

Date Code Title Description
FB Suspension of granting procedure